Clinical Trial Update: Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients [Phase 3]

View source ↗

Summary

Phase 3 trial data assess safety, tolerability, and efficacy of LCZ696 (sacubitril/valsartan) in Japanese patients with severe hypertension; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• LCZ696 (sacubitril/valsartan) (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Severe Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-09-07